The Most Oversold Stocks in the Health Care Sector

Investors looking for potential opportunities in the health care sector should pay attention to oversold stocks that may be undervalued. Oversold stocks can provide a chance to buy into companies at a lower price.

BioVie Inc. (BIVI)

• BioVie Inc. recently presented data for NE3107 at the 2023 International Congress of Parkinson’s Disease and Movement Disorders. The stock’s price has reached a 52-week low of $1.96.
• RSI Value: 26.01
• BIVI Price Action: On Tuesday, shares of BioVie fell approximately 1% to close at $3.06.

23andMe Holding Co. (ME)

• 23andMe Holding Co. recently announced that it has received FDA 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report. The stock’s price has reached a 52-week low of $0.9870.
• RSI Value: 29.59
• ME Price Action: On Tuesday, shares of 23andMe Holding fell 8% to close at $1.03.

Singular Genomics Systems, Inc. (OMIC)

• Singular Genomics Systems, Inc. recently posted a narrower-than-expected quarterly loss. The company has seen growth in its sales funnel and made advancements across its operations. The stock’s price has reached a 52-week low of $0.4560.
• RSI Value: 14.80
• OMIC Price Action: On Tuesday, shares of Singular Genomics Systems fell 0.9% to close at $0.4658.

Galera Therapeutics, Inc. (GRTX)

• Galera Therapeutics, Inc. recently reported a wider-than-expected quarterly loss, but the company is taking steps to extend its cash runway and seek FDA approval. The stock’s price has reached a 52-week low of $0.1960.
• RSI Value: 16.72
• GRTX Price Action: On Tuesday, shares of Galera Therapeutics gained 1.6% to close at $0.2151.

iSpecimen Inc. (ISPC)

• iSpecimen Inc. recently launched a new virtual cancer sequencing procurement program. The stock’s price has reached a 52-week low of $0.6818.
• RSI Value: 21.05
• ISPC Price Action: On Tuesday, shares of iSpecimen fell 1.5% to close at $0.7003.

Investors should consider conducting further research and analysis before making any investment decisions.